04.23.14
Phillips-Medisize Corp. reports that its facility in Suzhou, China, has begun full-scale production of a finished injector pen.
The company did not release the name of its customer, but claims it is "a leader in the development and manufacturing of delivery systems for drug self-administration."
The pens produced in the company’s China facility are for use in China and other Asian markets. The full ramp-up of the project represents the cornerstone of the company’s recently announced “China for China” strategy, meaning that products designed and manufactured in China will serve that region and not be shipped elsewhere such as the United States or Europe. The project, which started in 2011, included a global engineering team, led from Europe, which has successfully transferred this product into production. The program features molds built in Europe and China and an automated on-line scalable process, which produces a finished injector pen.
Matt Jennings, President and CEO of Phillips-Medisize Corp. said: “The start of production signifies the successful execution of our China for China strategy. The global Phillips-Medisize team is very excited about the attainment of this milestone, as it validates our fully-integrated capabilities for customers that desire products designed specifically for the China/Asia market and manufactured in a Chinese facility, all with state-of-the-art western medical quality systems and procedures.“
Phillips-Medisize China is located in the Suzhou Industrial Park and is ISO 13485 certified and China Food and Drug Administration registered. In addition to medical device, disposable diagnostics components, and drug-delivery device manufacturing, The company plans to open a design development center in Suzhou later this year. Other investments in the facility planned for 2014 include expanded office space, added molding capacity, and upgrades to mold repair and maintenance capabilities.
Hudson, Wisc.-based Phillips-Medisize is a global outsource provider of design and manufacturing services to the medical device and diagnostics, drug delivery, and commercial markets.
In addition to facilities in Wisconsin and California, the company has locations in China, Mexico, Switzerland, the Netherlands, Finland, Ireland and the Czech Republic.
The company did not release the name of its customer, but claims it is "a leader in the development and manufacturing of delivery systems for drug self-administration."
The pens produced in the company’s China facility are for use in China and other Asian markets. The full ramp-up of the project represents the cornerstone of the company’s recently announced “China for China” strategy, meaning that products designed and manufactured in China will serve that region and not be shipped elsewhere such as the United States or Europe. The project, which started in 2011, included a global engineering team, led from Europe, which has successfully transferred this product into production. The program features molds built in Europe and China and an automated on-line scalable process, which produces a finished injector pen.
Matt Jennings, President and CEO of Phillips-Medisize Corp. said: “The start of production signifies the successful execution of our China for China strategy. The global Phillips-Medisize team is very excited about the attainment of this milestone, as it validates our fully-integrated capabilities for customers that desire products designed specifically for the China/Asia market and manufactured in a Chinese facility, all with state-of-the-art western medical quality systems and procedures.“
Phillips-Medisize China is located in the Suzhou Industrial Park and is ISO 13485 certified and China Food and Drug Administration registered. In addition to medical device, disposable diagnostics components, and drug-delivery device manufacturing, The company plans to open a design development center in Suzhou later this year. Other investments in the facility planned for 2014 include expanded office space, added molding capacity, and upgrades to mold repair and maintenance capabilities.
Hudson, Wisc.-based Phillips-Medisize is a global outsource provider of design and manufacturing services to the medical device and diagnostics, drug delivery, and commercial markets.
In addition to facilities in Wisconsin and California, the company has locations in China, Mexico, Switzerland, the Netherlands, Finland, Ireland and the Czech Republic.